Identification of biomarkers for patients with Mucopolysaccharidoses

22 Mar 2016, 6:04 p.m.

Dr Wendy Heywood and team

Researchers have identified urine biomarkers that are altered in patients with Mucopolysaccharidoses (MPS). The team, led by Great Ormond Street BRC-funded Dr Wendy Heywood, discovered potential surrogate urine markers linked to known pathological features of MPS. The test was able to show a relationship between marker concentrations and disease severity.

In mild cases of MPS, markers were not significantly raised in comparison to controls, while three markers were able to stratify the severe neurological form of the disease – known as MPS II or Hunter syndrome – and the less severe, non-neurological clinical phenotype.

MPS is a genetic lysosomal storage disorder resulting from the body’s inability to produce specific enzymes that degrade large complex sugar molecules also known as glycosaminoglycans (GAGs). Accumulation of GAGs causes progressive cellular damage, multi organ failure and a reduced life expectancy. MPS is currently diagnosed by analysis of urinary GAG species, but GAG analysis is limited when it comes to discriminating mild and severe phenotypes of MPS I and MPS II.

The development of markers into a translatable assay has the potential to determine the severity of a patient’s disease at the point of diagnosis – where the initiation of treatment is crucial – and has further potential to monitor the effect of treatment in MPS patients.

This research was funded as part of the Great Ormond Street BRC-supported infrastructure GOSomics and was published in Analytical Chemistry.

Toddler doing well after receiving newest gene therapy available on NHS

A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Genes may help to predict which children will respond well to arthritis treatment

A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.

Making it easier to invest in frontline care

GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.

Patients and public help create multilingual resources for expectant parents

A group of clinicians and researchers at GOSH have developed information about a test offered in pregnancy called prenatal sequencing in the UK’s 12 most common languages.